Effect of a Community Health Worker-Led Multicomponent Intervention on Blood Pressure Control in Low-Income Patients in Argentina: A Randomized Clinical Trial

Jiang He, Vilma Irazola, Katherine T Mills, Rosana Poggio, Andrea Beratarrechea, Jacquelyn Dolan, Chung-Shiuan Chen, Luz Gibbons, Marie Krousel-Wood, Lydia A Bazzano, Analia Nejamis, Pablo Gulayin, Marilina Santero, Federico Augustovski, Jing Chen, Adolfo Rubinstein, HCPIA Investigators, Jiang He, Vilma Irazola, Katherine T Mills, Rosana Poggio, Andrea Beratarrechea, Jacquelyn Dolan, Chung-Shiuan Chen, Luz Gibbons, Marie Krousel-Wood, Lydia A Bazzano, Analia Nejamis, Pablo Gulayin, Marilina Santero, Federico Augustovski, Jing Chen, Adolfo Rubinstein, HCPIA Investigators

Abstract

Importance: Despite extensive knowledge of hypertension treatment, the prevalence of uncontrolled hypertension is high and increasing in low- and middle-income countries.

Objective: To test whether a community health worker-led multicomponent intervention would improve blood pressure (BP) control among low-income patients with hypertension.

Design, setting, and participants: A cluster randomized trial was conducted in 18 centers for primary health care within a national public system providing free medications and health care to uninsured patients in Argentina. A total of 1432 low-income adult patients with uncontrolled hypertension were recruited between June 2013 and April 2015 and followed up to October 2016.

Interventions: Nine centers (743 patients) were randomized to the multicomponent intervention, which included a community health worker-led home intervention (health coaching, home BP monitoring, and BP audit and feedback), a physician intervention, and a text-messaging intervention over 18 months. Nine centers (689 patients) were randomized to usual care.

Main outcomes and measures: The coprimary outcomes were the differences in systolic and diastolic BP changes from baseline to the end of follow-up of patients with hypertension. Secondary outcomes included the proportion of patients with controlled hypertension (BP <140/90 mm Hg). Three BP measurements were obtained at each of 2 baseline and 2 termination visits using a standard protocol, the means of which were used for analyses.

Results: Of 1432 participants (mean age, 55.8 years [SD, 13.3]; 772 women [53.0%]), 1357 (94.8%) completed the trial. Baseline mean systolic BP was 151.7 mm Hg for the intervention group and 149.8 mm Hg for the usual care group; the mean diastolic BP was 92.2 mm Hg for the intervention group and 90.1 mm Hg for the usual care group. Systolic BP reduction from baseline to month 18 was 19.3 mm Hg (95% CI, 17.9-20.8 mm Hg) for the intervention group and 12.7 mm Hg (95% CI, 11.3-14.2 mm Hg) for the usual care group; the difference in the reduction was 6.6 mm Hg (95% CI, 4.6-8.6; P < .001). Diastolic BP decreased by 12.2 mm Hg (95% CI, 11.2-13.2 mm Hg) in the intervention group and 6.9 mm Hg (95% CI, 5.9-7.8 mm Hg) in the control group; the difference in the reduction was 5.4 mm Hg (95% CI, 4.0-6.8 mm Hg; P < .001). The proportion of patients with controlled hypertension increased from 17.0% at baseline to 72.9% at 18 months in the intervention group and from 17.6% to 52.2% in the usual care group; the difference in the increase was 20.6% (95% CI, 15.4%-25.9%; P < .001). No adverse events were reported.

Conclusions and relevance: Low-income patients in Argentina with uncontrolled hypertension who participated in a community health worker-led multicomponent intervention experienced a greater decrease in systolic and diastolic BP than did patients who received usual care over 18 months. Further research is needed to assess generalizability and cost-effectiveness of this intervention and to understand which components may have contributed most to the outcome.

Trial registration: clinicaltrials.gov Identifier: NCT01834131.

Conflict of interest statement

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

Figures

Figure 1. Flow diagram of trial participants
Figure 1. Flow diagram of trial participants
Normotensive participants were spouses of hypertensive participants who had systolic blood pressure

Figure 2. Mean blood pressure during trial…

Figure 2. Mean blood pressure during trial follow-up in intervention and control groups among patients…

Figure 2. Mean blood pressure during trial follow-up in intervention and control groups among patients with hypertension
Systolic blood pressure (upper panel) and diastolic blood pressure (lower panel). Six blood pressure measurements at baseline and 18 months from two visits as well as three blood pressure measurements at 6 months and 12 months from one visit were obtained. The point estimates are mean blood pressure and error bars indicate 95% confidence intervals.

Figure 3. Mean difference in the changes…

Figure 3. Mean difference in the changes of systolic and diastolic blood pressure among patients…

Figure 3. Mean difference in the changes of systolic and diastolic blood pressure among patients with hypertension by subgroups
Mean differences in systolic (upper panel) and diastolic (lower panel) blood pressure changes from baseline to 18-month follow-up between the intervention and control groups. Data markers indicate mean difference in the changes and error bars indicate 95% confidence intervals. High cardiovascular risk subgroup includes participants with a history of coronary heart disease, heart failure, stroke, hypercholesterolemia, or diabetes.

Figure 3. Mean difference in the changes…

Figure 3. Mean difference in the changes of systolic and diastolic blood pressure among patients…

Figure 3. Mean difference in the changes of systolic and diastolic blood pressure among patients with hypertension by subgroups
Mean differences in systolic (upper panel) and diastolic (lower panel) blood pressure changes from baseline to 18-month follow-up between the intervention and control groups. Data markers indicate mean difference in the changes and error bars indicate 95% confidence intervals. High cardiovascular risk subgroup includes participants with a history of coronary heart disease, heart failure, stroke, hypercholesterolemia, or diabetes.
Figure 2. Mean blood pressure during trial…
Figure 2. Mean blood pressure during trial follow-up in intervention and control groups among patients with hypertension
Systolic blood pressure (upper panel) and diastolic blood pressure (lower panel). Six blood pressure measurements at baseline and 18 months from two visits as well as three blood pressure measurements at 6 months and 12 months from one visit were obtained. The point estimates are mean blood pressure and error bars indicate 95% confidence intervals.
Figure 3. Mean difference in the changes…
Figure 3. Mean difference in the changes of systolic and diastolic blood pressure among patients with hypertension by subgroups
Mean differences in systolic (upper panel) and diastolic (lower panel) blood pressure changes from baseline to 18-month follow-up between the intervention and control groups. Data markers indicate mean difference in the changes and error bars indicate 95% confidence intervals. High cardiovascular risk subgroup includes participants with a history of coronary heart disease, heart failure, stroke, hypercholesterolemia, or diabetes.
Figure 3. Mean difference in the changes…
Figure 3. Mean difference in the changes of systolic and diastolic blood pressure among patients with hypertension by subgroups
Mean differences in systolic (upper panel) and diastolic (lower panel) blood pressure changes from baseline to 18-month follow-up between the intervention and control groups. Data markers indicate mean difference in the changes and error bars indicate 95% confidence intervals. High cardiovascular risk subgroup includes participants with a history of coronary heart disease, heart failure, stroke, hypercholesterolemia, or diabetes.

References

    1. Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA. 2017;317(2):165–182.
    1. He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353(11):1124–34.
    1. Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441–50.
    1. He J, Muntner P, Chen J, Roccella EJ, Streiffer RH, Whelton PK. Factors associated with hypertension control in the general population of the United States. Arch Intern Med. 2002;162(9):1051–8.
    1. Odedosu T, Schoenthaler A, Vieira DL, Agyemang C, Ogedegbe G. Overcoming barriers to hypertension control in African Americans. Cleve Clin J Med. 2012;79(1):46–56.
    1. Santschi V, Chiolero A, Colosimo AL, et al. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc. 2014;3(2):e000718. doi: 10.1161/JAHA.113.000718.
    1. Clark CE, Smith LF, Taylor RS, Campbell JL. Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis. BMJ. 2010;341:c3995. doi: 10.1136/bmj.c3995.
    1. Ogedegbe G, Gyamfi J, Plange-Rhule J, et al. Task shifting interventions for cardiovascular risk reduction in low-income and middle-income countries: a systematic review of randomised controlled trials. BMJ Open. 2014;4(10):e005983. doi: 10.1136/bmjopen-2014-005983.
    1. Mills KT, Rubinstein A, Irazola V, et al. Comprehensive approach for hypertension control in low-income populations: rationale and study design for the hypertension control program in Argentina. Am J Med Sci. 2014;348(2):139–45.
    1. World Bank. [Accessed February 7, 2017];The health sector in Argentina: current situations and options for improvement. .
    1. Belló M1, Becerril-Montekio VM. The health system of Argentina. Salud Publica Mex. 2011;53(Suppl 2):s96–s108.
    1. Homedes N, Ugalde A. Improving access to pharmaceuticals in Brazil and Argentina. Health Policy Plan. 2006;21(2):123–31.
    1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA. 2003;289(19):2560–72.
    1. Sanchez RA, Ayala M, Baglivo H, et al. Latin American guidelines on hypertension. Latin American Expert Group. J Hypertens. 2009;27(5):905–22.
    1. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans: an AHA scientific statement from the Council on High Blood Pressure Research Professional and Public Education Subcommittee. J Clin Hypertens (Greenwich) 2005;7(2):102–9.
    1. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care. 1986;24(1):67–74.
    1. Adams G, Gulliford MC, Ukoumunne OC, Eldridge S, Chinn S, Campbell MJ. Patterns of intra-cluster correlation from primary care research to inform study design and analysis. J Clin Epidemiol. 2004;57(8):785–94.
    1. Donner A, Klar N. Statistical considerations in the design and analysis of community intervention trials. J Clin Epidemiol. 1996;49(4):435–439.
    1. Ramsey SD, Willke RJ, Glick H, et al. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. Value Health. 2015;18(2):161–72.
    1. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation. Health Economics. 1997;6(4):327–40.
    1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128.
    1. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–67.
    1. Gu D, He J, Coxson PG, et al. The cost-effectiveness of low-cost essential antihypertensive medicines for hypertension control in China: a modelling study. PLoS Med. 2015;12(8):e1001860. doi: 10.1371/journal.pmed.1001860.
    1. Steinberg D, Bennett GG, Svetkey L. The DASH Diet, 20 Years Later. JAMA. 2017;317(15):1529–1530.
    1. Committee on Public Health Priorities to Reduce and Control Hypertension in the U.S. Population, Institute of Medicine. A population-based policy and systems change approach to prevent and control hypertension. Washington DC: National Academy Press; 2010.
    1. Glynn LG, Murphy AW, Smith SM, Schroeder K, Fahey T. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2010;3:CD005182.
    1. Roumie CL, Elasy TA, Greevy R, et al. Improving blood pressure control through provider education, provider alerts, and patient education: a cluster randomized trial. Ann Intern Med. 2006;145(3):165–75.
    1. Pladevall M, Brotons C, Gabriel R, et al. Multicenter cluster-randomized trial of a multifactorial intervention to improve antihypertensive medication adherence and blood pressure control among patients at high cardiovascular risk (the COM99 study) Circulation. 2010;122(12):1183–91.
    1. Ogedegbe G, Tobin JN, Fernandez S, et al. Counseling African Americans to Control Hypertension: cluster-randomized clinical trial main effects. Circulation. 2014;129(20):2044–51.
    1. Jafar TH, Hatcher J, Poulter N, et al. Community-based interventions to promote blood pressure control in a developing country: a cluster randomized trial. Ann Intern Med. 2009;151(9):593–601.
    1. Brownstein JN, Chowdhury FM, Norris SL, et al. Effectiveness of community health workers in the care of people with hypertension. Am J Prev Med. 2007;32(5):435–447.
    1. Soriano ER, Dawidowski AR, Pereiro N, et al. Gaps between prescription of anti-hypertensive and hypertension control in older adults of Buenos Aires suburbs. Rev Fac Cien Med Univ Nac Cordoba. 2011;68(4):141–8.
    1. Brierley G, Brabyn S, Torgerson D, Watson J. Bias in recruitment to cluster randomized trials: a review of recent publications. J Eval Clin Pract. 2012;18(4):878–86.
    1. Gu D, He J, Coxson PG, Rasmussen PW, Huang C, Thanataveerat A, et al. The cost-effectiveness of low-cost essential antihypertensive medicines for hypertension control in China: a modelling study. PLoS Med. 2015;12(8):e1001860. doi: 10.1371/journal.pmed.1001860.

Source: PubMed

3
Subscribe